Form F-1 BioNTech SE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
http://archive.fast-edgar.com/20200721/A822QQ2DZZ2RCZZK22ZD2ZYKB8GREZ22Z22Q
Filed on: July 21, 2020
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech to adapt breast cancer trial to pair pumitamig with Gilead drug
- BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
- XAI Floating Rate & Alternative Income Trust Will Host its Q3 2026 Quarterly Webinar on November 2, 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
